Viva Biotech Holdings (HKG:1873)

Viva Biotech Holdings Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,089	941.71	1,036	678.57	800.95
Cash & Short-Term Investments	1,089	941.71	1,036	678.57	800.95
Cash Growth	15.62%	-9.13%	52.72%	-15.28%	-66.03%
Accounts Receivable	386.3	420.46	407.41	445.97	429.7
Other Receivables	242.94	61.24	136.13	59.41	102.2
Receivables	629.24	481.7	543.53	505.38	531.9
Inventory	335.74	272.7	259.71	326.03	231.72
Prepaid Expenses	9.34	8.31	5.95	7.94	7.26
Other Current Assets	65.1	50.45	185.41	420.88	411.95
Total Current Assets	2,128	1,755	2,031	1,939	1,984
Property, Plant & Equipment	1,535	1,597	1,655	1,937	1,724
Long-Term Investments	873.57	988.55	1,038	1,047	1,247
Goodwill	2,156	2,156	2,156	2,156	2,156
Other Intangible Assets	311.49	366.05	420.67	476.06	531.44
Long-Term Accounts Receivable	2.93	3.51	5.25	6.43	16.12
Long-Term Deferred Tax Assets	35.86	28.03	21.19	18.18	7.63
Other Long-Term Assets	156.21	155.86	122.76	340.97	378.73
Total Assets	7,199	7,051	7,450	7,921	8,045

Liabilities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	212.24	309.36	245.76	326.13	281.05
Accrued Expenses	101.12	98.01	133.35	140.37	105.85
Short-Term Debt	575.33	260.71	538.03	373.94	228.9
Current Portion of Long-Term Debt	394.23	288.68	411.48	1,540	4.15
Current Portion of Leases	2.79	3.09	2.93	2.27	5.69
Current Income Taxes Payable	23.23	28.87	32.02	41.63	41.31
Current Unearned Revenue	38.46	50.98	36.42	44.24	50.01
Other Current Liabilities	63.76	86.95	134.19	204	209.64
Total Current Liabilities	1,411	1,127	1,534	2,673	926.6
Long-Term Debt	331.19	705.92	922.01	880.96	2,388
Long-Term Leases	27.05	25.65	28.76	25.8	27.77
Long-Term Unearned Revenue	29.42	33	55.02	73.12	75.27
Pension & Post-Retirement Benefits	4.14	6.34	-	-	-
Long-Term Deferred Tax Liabilities	68.2	73.85	69.19	92.2	117.73
Other Long-Term Liabilities	1,322	1,263	1,153	571.5	595.85
Total Liabilities	3,193	3,234	3,762	4,316	4,131

Shareholders' Equity

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.36	0.37	0.37	0.33	0.33
Additional Paid-In Capital	3,842	3,874	3,874	3,637	3,637
Retained Earnings	92.55	-127.21	-294.51	-178.4	350.08
Treasury Stock	-129.04	-157.67	-134.65	-134.65	-134.65
Comprehensive Income & Other	190.43	212.73	242.54	280.48	60.65
Total Common Equity	3,997	3,802	3,688	3,605	3,913
Minority Interest	9.78	13.84	-	-	-
Shareholders' Equity	4,006	3,816	3,688	3,605	3,913
Total Liabilities & Equity	7,199	7,051	7,450	7,921	8,045

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,331	1,284	1,903	2,823	2,655
Net Cash (Debt)	-241.82	-342.34	-866.9	-2,144	-1,854
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-0.10	-0.12	-0.43	-1.12	-0.94
Filing Date Shares Outstanding	2,111	2,113	2,142	1,915	1,915
Total Common Shares Outstanding	2,111	2,113	2,142	1,915	1,915
Working Capital	717.03	628.21	496.74	-733.75	1,057
Book Value Per Share	1.89	1.80	1.72	1.88	2.04
Tangible Book Value	1,529	1,280	1,111	972.23	1,225
Tangible Book Value Per Share	0.72	0.61	0.52	0.51	0.64
Buildings	773.8	759.47	558.65	553.56	293.19
Machinery	985.65	926.64	805.36	703.13	552.49
Construction In Progress	93.5	109.54	338.48	469.88	542.03
Leasehold Improvements	21.85	26.29	26.29	26.29	37.07
Order Backlog	-	-	-	-	965

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 17, 2026

Data Sources Report a data error